P

Prime Medicine Inc
NASDAQ:PRME

Watchlist Manager
Prime Medicine Inc
NASDAQ:PRME
Watchlist
Price: 2.9 USD 3.94% Market Closed
Market Cap: 380.4m USD
Have any thoughts about
Prime Medicine Inc?
Write Note

Prime Medicine Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Prime Medicine Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
P
Prime Medicine Inc
NASDAQ:PRME
Retained Earnings
-$491.3m
CAGR 3-Years
-334%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Retained Earnings
-$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Retained Earnings
-$25.5B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Retained Earnings
$8.7B
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Retained Earnings
$30.8B
CAGR 3-Years
22%
CAGR 5-Years
36%
CAGR 10-Years
71%
No Stocks Found

Prime Medicine Inc
Glance View

Market Cap
380.4m USD
Industry
Biotechnology

Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.

PRME Intrinsic Value
1.69 USD
Overvaluation 42%
Intrinsic Value
Price
P

See Also

What is Prime Medicine Inc's Retained Earnings?
Retained Earnings
-491.3m USD

Based on the financial report for Dec 31, 2023, Prime Medicine Inc's Retained Earnings amounts to -491.3m USD.

What is Prime Medicine Inc's Retained Earnings growth rate?
Retained Earnings CAGR 3Y
-334%

Over the last year, the Retained Earnings growth was -68%. The average annual Retained Earnings growth rates for Prime Medicine Inc have been -334% over the past three years .

Back to Top